Trial reportJournal of the American College of Cardiology2021
Progression of Tricuspid Regurgitation After Surgery for Ischemic Mitral Regurgitation.
Trial report in Journal of the American College of Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Surgical Interventions for Moderate Ischemic Mitral Regurgitation
Evaluation of Outcomes Following Mitral Valve Repair/Replacement in Severe Chronic Ischemic Mitral Regurgitation
Who cites it
14 citing papers in PubMed, 38 citations in OpenAlex.
- Isolated secondary tricuspid regurgitation after left-sided valve surgery: impact on clinical outcomes.Open heart · 2026Observational
- Longitudinal Data Sets in Cardiac Surgery.The Annals of thoracic surgery · 2026Review
- Exploration of Anesthetic Strategies for Transcatheter Tricuspid Valve Intervention.Reviews in cardiovascular medicine · 2026Review
- Risk factors for long-term severe tricuspid regurgitation following mitral valve replacement: a retrospective study.BMC cardiovascular disorders · 2025Article
- Types of Complications and Associated Factors in Patients Undergoing Permanent Cardiac Pacemaker Implantation: A Systematic Review.Journal of multidisciplinary healthcare · 2025Review
- Society of cardiothoracic surgery in great Britain and Ireland guidance for adult mitral valve disease and interventions.BMJ surgery, interventions, & health technologies · 2025Article
- Association of tricuspid regurgitation with clinical events and quality of life after surgery for severe ischemic mitral regurgitation.JTCVS structural and endovascular · 2024Article
- Concomitant Tricuspid Valve Surgery With Mitral Valve Surgery for Moderate Tricuspid Regurgitation.Annals of thoracic surgery short reports · 2024Article
- Present and Future Surgical Options for Tricuspid Regurgitation.Reviews in cardiovascular medicine · 2024Review
- Tricuspid surgery at time of mitral surgery improves survival free from severe tricuspid regurgitation but not quality of life.JTCVS open · 2023Article
- Does concomitant tricuspid valve surgery increase the risks of minimally invasive mitral valve surgery? A multicentre comparison based on data from The Netherlands Heart Registration.Journal of cardiac surgery · 2022Article
- Outcomes and risk analysis after tricuspid valve surgery for non-Ebstein 2-ventricle congenital tricuspid valve diseases.JTCVS open · 2022Article
- Surgical management of tricuspid regurgitation: a new algorithm to minimise recurrent tricuspid regurgitation.Open heart · 2022Observational
- Diagnosis and Management of Failed Surgical Tricuspid Valve Annuloplasty.Current cardiology reports · 2021Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
21 authors at 12 institutions in 1 country.
Funding
Abstract
backgroundWhether to repair nonsevere tricuspid regurgitation (TR) during surgery for ischemic mitral valve regurgitation (IMR) remains uncertain.
objectivesThe goal of this study was to investigate the incidence, predictors, and clinical significance of TR progression and presence of ≥moderate TR after IMR surgery.
methodsPatients (n = 492) with untreated nonsevere TR within 2 prospectively randomized IMR trials were included. Key outcomes were TR progression (either progression by ≥2 grades, surgery for TR, or severe TR at 2 years) and presence of ≥moderate TR at 2 years.
resultsPatients' mean age was 66 ± 10 years (67% male), and TR distribution was 60% ≤trace, 31% mild, and 9% moderate. Among 2-year survivors, TR progression occurred in 20 (6%) of 325 patients. Baseline tricuspid annular diameter (TAD) was not predictive of TR progression. At 2 years, 37 (11%) of 323 patients had ≥moderate TR. Baseline TR grade, indexed TAD, and surgical ablation for atrial fibrillation were independent predictors of ≥moderate TR. However, TAD alone had poor discrimination (area under the curve, ≤0.65). Presence of ≥moderate TR at 2 years was higher in patients with MR recurrence (20% vs. 9%; p = 0.02) and a permanent pacemaker/defibrillator (19% vs. 9%; p = 0.01). Clinical event rates (composite of ≥1 New York Heart Association functional class increase, heart failure hospitalization, mitral valve surgery, and stroke) were higher in patients with TR progression (55% vs. 23%; p = 0.003) and ≥moderate TR at 2 years (38% vs. 22%; p = 0.04).
conclusionsAfter IMR surgery, progression of unrepaired nonsevere TR is uncommon. Baseline TAD is not predictive of TR progression and is poorly discriminative of ≥moderate TR at 2 years. TR progression and presence of ≥moderate TR are associated with clinical events. (Comparing the Effectiveness of a Mitral Valve Repair Procedure in Combination With Coronary Artery Bypass Grafting [CABG] Versus CABG Alone in People With Moderate Ischemic Mitral Regurgitation, NCT00806988; Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation, NCT00807040).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.